AsymBio, a subsidiary of China-based Asymchem Group (SZ:002821) (HK:6821), announced on Tuesday that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle, providing end-to-end services from early development through commercial manufacturing.

Core capabilities include the AmigoCHO cell line development platform and upstream and downstream process development platforms, supporting clone selection, process optimisation, scale-up, and characterisation, with certain project timelines reduced to as little as nine weeks. Its Conjugation Toolbox enables modular development across multiple bioconjugate modalities, including ADCs, RDCs, AOCs, and APCs, and was shortlisted for Best ADC Platform Technology at the 2025 World ADC Awards.

The IMPACT drug product development platform offers phase-accountable services across high-concentration, lyophilised, liquid, and frozen-liquid formulations. AsymBio's Payload-Linker CMC development platform supports more than 70 IND and 13 NDA projects, while its comprehensive analytical platform provides method development and product characterisation across critical quality attributes throughout the product lifecycle.